Shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.36 and traded as low as $0.28. Avenue Therapeutics shares last traded at $0.3053, with a volume of 1,129 shares changing hands.
Avenue Therapeutics Price Performance
The business’s 50 day simple moving average is $0.46 and its 200-day simple moving average is $0.36. The stock has a market capitalization of $1.01 million, a P/E ratio of 0.02 and a beta of -0.32.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company has concentrated primarily on hospital-based treatments, with the goal of addressing pain management needs while offering alternatives to conventional opioid therapies.
Avenue’s lead product candidate is intravenous (IV) tramadol, an investigational formulation of tramadol hydrochloride intended for the management of acute postoperative pain in adults who require an intravenous analgesic.
Read More
- Five stocks we like better than Avenue Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
